Our Research
Gynecological Oncology
CBP-1008:Platinum-resistant ovarian cancer (PROC)
CBP-1019:Platinum-resistant ovarian cancer (PROC)
CBP-1019:Platinum-resistant ovarian cancer (PROC)
Genitourinary Oncology
CBP-1018:Metastatic castration-resistant prostate cancer (mCRPC)
Renal cell carcinoma (RCC)
CBP-8088:Metastatic castration-resistant prostate cancer (mCRPC)
CBP-8088:Metastatic castration-resistant prostate cancer (mCRPC)
Gastrointestinal Cancer
CBP-1019:Pancreatic cancer
Thoracic Malignancies
CBP-1008:Triple-negative breast cancer (TNBC)
CBP-1018:Lung cancer (LC)
CBP-1019:Lung cancer (LC)
CBP-8088:Triple-negative breast cancer (TNBC)
CBP-1018:Lung cancer (LC)
CBP-1019:Lung cancer (LC)
CBP-8088:Triple-negative breast cancer (TNBC)
Bone Metastases
CBP-1018
CBP-1203
CBP-1203
Pipeline
Product
Indications
Target
Payload
Pre-clinical
IND enabling
Phase I
Phase II/III
NDA
CBP-1008
Ovarian cancer
Breast cancer
FRα × TRPV6
Tubulin
Inhibitor
CBP-1018
Prostate cancer
Bone metastases
FRα × TRPV6
Tubulin
Inhibitor
CBP-1019
Ovarian cancer
Lung cancer
Gastrointestinal Onco
Genitourinary Onco
FRα × TRPV6
Topoisomerase Inhibitor
CBP-1029
Solid cancer
EGFR × cMET
Topoisomerase Inhibitor
CBP-8088
Prostate cancer
TNBC
undisclosed
PROTAC
CBP-1039
Solid cancer
undisclosed
Topoisomerase Inhibitor
CBP-1203
Solid cancer
undisclosed
Radioactive Isotope
CBP-1602
Solid cancer
undisclosed
Photodynamic Therapies